Beranda › Kanker Paru Non-Sel Kecil › Virginia › Arlington
Uji klinis Kanker Paru Non-Sel Kecil di Arlington, VA
104 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Arlington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax · 11 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Inova Schar Cancer Institute, Fairfax · 11 mi jauhnya
- NEXT Virginia, Fairfax · 11 mi jauhnya
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- Virginia Cancer Specialists ( Site 0167), Fairfax · 11 mi jauhnya
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Menerima pesertaFase 2/3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi jauhnya
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Menerima pesertaFase 3
- Virginia Cancer Specialists ( Site 0114), Fairfax · 11 mi jauhnya
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Menerima pesertaFase 1
- Site 04, Fairfax · 11 mi jauhnya
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Menerima pesertaFase 1
- ALX Center 2, Fairfax · 11 mi jauhnya
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Menerima pesertaFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Fairfax · 11 mi jauhnya
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 1
- Virginia Cancer Specialists PC, Fairfax · 11 mi jauhnya
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Research Site, Fairfax · 11 mi jauhnya
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Menerima pesertaFase 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Menerima pesertaFase 1/2
- Inova Schar Cancer Institute Clinical Trials, Fairfax · 11 mi jauhnya
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Menerima pesertaFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · 11 mi jauhnya
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Research Site, Fairfax · 11 mi jauhnya
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Fairfax · 11 mi jauhnya
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Menerima pesertaFase 3
- Virginia Cancer Specialists, Arlington
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Menerima pesertaFase 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi jauhnya
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- NEXT - Virginia, Fairfax · 11 mi jauhnya
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- Local Institution - 007-814-D, Arlington
- USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax · 11 mi jauhnya
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Menerima pesertaFase 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi jauhnya
- Next Oncology Virginia, Fairfax · 11 mi jauhnya
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Virginia Cancer Specialists (Fairfax) - USOR, Fairfax · 11 mi jauhnya
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi jauhnya
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Menerima pesertaFase 3
- USO - Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Menerima pesertaFase 3
- Research Site, Fairfax · 11 mi jauhnya
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Menerima pesertaFase 1
- NEXT Oncology, Fairfax · 11 mi jauhnya
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Menerima pesertaFase 1
- Virginia Cancer Specialists, PC, Fairfax · 11 mi jauhnya
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Menerima pesertaFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Fairfax · 11 mi jauhnya
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Menerima pesertaFase 1
- Inova Schar Cancer Institute, Falls Church · 4 mi jauhnya
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Fairfax · 11 mi jauhnya
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Menerima pesertaFase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi jauhnya
- Inova Fair Oaks Hospital, Fairfax · 11 mi jauhnya
A Study of DM005 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Clinical Trial Site, Fairfax · 11 mi jauhnya
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Next Virginia, Fairfax · 11 mi jauhnya
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Menerima pesertaFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Menerima pesertaFase 1/2
- Research Site, Fairfax · 11 mi jauhnya
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Research Site, Fairfax · 11 mi jauhnya
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Menerima pesertaFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
A Study of LY4175408 in Participants With Advanced Cancer
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · 11 mi jauhnya
Study of XB010 in Subjects With Solid Tumors
Menerima pesertaFase 1
- Inova Schar Cancer, Fairfax · 11 mi jauhnya
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Menerima pesertaFase 1
- NEXT Texas LLC - Virginia, Fairfax · 11 mi jauhnya
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Research Site, Fairfax · 11 mi jauhnya
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Fairfax · 11 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Menerima pesertaFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Menerima pesertaFase 1/2
- NEXT Oncology, Fairfax · 11 mi jauhnya
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Menerima pesertaFase 1
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Next Oncology Virginia, Fairfax · 11 mi jauhnya
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Fairfax · 11 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi jauhnya
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Menerima pesertaFase 2
- Inova Fairfax Hospital, Fairfax · 11 mi jauhnya
A 2-part Phase 1/2 Open-label Trial on ODM-212
Menerima pesertaFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi jauhnya
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Menerima pesertaFase 1
- Research Site, Fairfax · 11 mi jauhnya
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- NEXT Virginia, Fairfax · 11 mi jauhnya
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Menerima pesertaFase 1/2
- NEXT, Virginia, Fairfax · 11 mi jauhnya
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Fairfax · 11 mi jauhnya
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Menerima pesertaFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Menerima pesertaFase 1
- NEXT Oncology, Fairfax · 11 mi jauhnya
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 102, Fairfax · 11 mi jauhnya
- Research Site 112, Fairfax · 11 mi jauhnya
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi jauhnya
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Menerima pesertaFase 1/2
- NEXT Virginia, Fairfax · 11 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
- Seattle, WA53 studi
Studi lain di Arlington
- Kanker Metastatik53 studi
- Kanker Kolorektal52 studi
- Kanker (semua jenis)48 studi
- Kanker Payudara47 studi
- Kanker Ovarium46 studi
- Kanker Paru41 studi
- Kanker Endometrium39 studi
- Kanker Pankreas33 studi
- Karsinoma Sel Skuamosa Kepala dan Leher26 studi
- Kanker Paru Sel Kecil23 studi
- Kanker Lambung20 studi
- Kanker Payudara Triple-Negatif20 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.